抗血小板聚集药在缺血性脑卒中的应用..doc

医学综述 2012 年 1 月第 18 卷第 1 期 M edical Recapitulate, J an. 2012, Vol. 18, No. 1 ? 139? small contribution to warfar in dose requirem ents[J]. Phar macogen-et Genomics, 2006, 16(8 :609-611. Huang S, Chen B, Xiang D, et al . Association betw een apolipopr o-tein E gene polym orphism and dose for war farin ma intena nce[J]. Zhong Nan Da Xue Xue Bao Yi Xue Ban, 2011, 36(3 :212-216. Wadelius M , S r lin K, Wallerma n O, et al . Warfa rin sensitivity r e-lated to CYP2C9, C YP 3A5, ABCB 1(MDR1 and other factor s[J]. Pharmacogenom ics J , 2004, 4(1 :40-48. M ega J L, Close S L, Wiviott S D, et al . Genetic var ia nts in ABCB 1 and CYP2C 19and ca rdiovascular outcomes after tr eatment w ith clopidog rel and pr asugr el in the TRITON-TIMI 38tr ial:a phar ma-cogenetic a nalysis[J]. Lancet, 2010, 376(9749 :1312-1319. [20] Kimur a R, M iyashita K, Kokubo Y, et al . Genotypes of vitamin K epoxide reductase, gamma-glutamyl car box ylase, and cytochr ome P 4502C9as determinants of daily wa rfarin dose in J apanese pa-tients[J]. Throm b Res, 2007, 120(2 :181-186. Zhong S L, Liu Y, Yu XY, et al . The influence of genetic polymor-phisms and interacting dr ugs on initial response to war farin in C hi-nese patients with hear t valve replacement[J]. Eur J Clin Phar ma-col, 2011, 67(6 :581-590. Luxembourg B, S chneider K, Sittinger K, et al . Impa ct of pharm aco-kinetic(CYP 2C 9 a nd pharmacodynamic (VKORC1, F7, GGCX, CALU, EPHX1 gene var iants on the initiation and maintena nce pha ses of phenprocoumon ther apy[J ]. Thromb Haemost, 2011, 105(1 :169-180. Vecsler M, Loebstein R, Almog S, et al . Combined genetic profiles of components and r egula tors of the vitam in K-dependent g amma-carboxylation sy stem a ffect individual sensitivity to w arfar in [J]. Thromb Haemost, 2006, 95(2 :205-211. Cara co Y, B lotnick S, Muszkat M, et al . CYP2C 9genotype-guided warfar in prescribing enhances the efficacy and safety of anticoagu-lation:a prospective r andomized contr olled study[J ]. C lin Pharm